• significantly reduced total plasma cholesterol

• significantly reduced free cholesterol

• significantly reduced levels of esterified cholesterol

• significantly reduced HDL cholesterol

• lower than in absence of transgene

• faster plasma HDL catabolism

• significantly reduced phospolipid levels

• human apoA-I not detectable in plasma

• two fold increase in HDL catabolism in the kidney

• moderately reduced total plasma cholesterol

• moderately reduced free cholesterol

• 50% reduction of esterified cholesterol

• moderately reduced HDL cholesterol

• less reduction of phospolipid levels than expected

• less reduction of human apoA-I in plasma than expected